Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis — RAPAMI

Inclusion Body Myositis (IBM) Clinical Trial

Official title:
Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI"

Status Completed

Clinical Trial Summary

Sporadic Inclusion Body Myositis (IBM) is the most frequent inflammatory myopathy in patients over 50. It is a slowly progressive, but today untreatable (notably by classical immunosuppressants) disease.

Rapamycin used in organ transplantation blocks the activity of T effector cells, preserves T regulatory cells and induces autophagy (protein degradation), all parameters impaired during IBM.

RAPAMI is a prospective, randomised, controlled, double blind, monocentric, phase IIb trial evaluating rapamycine against placebo.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02481453
Study type	Interventional
Source	Institut National de la Santé Et de la Recherche Médicale, France
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	July 15, 2015
Completion date	January 22, 2018

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT06450886` - Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis	Phase 2/Phase 3
	Active, not recruiting	`NCT02483845` - Natalizumab in Inclusion Body Myositis (IBM)	Phase 1